Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 402Other solid neoplasm 31Gastrointestinal 24CNS 20Gynecologic 18Head & Neck 16Breast 14Genitourinary 12Sarcoma 8Tumor-Agnostic 5Endocrine 3Dermatologic 3NET 2Lymphoid 2

Conditions

Neuroendocrine Tumors 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Recurrence 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Pemetrexed × Endocrine × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT00786552 2011-01-20

Panthera

University Hospital Schleswig-Holstein

Phase 2 Unknown
47 enrolled
EndocrineHead & Neck

Recurrence, Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00424723 2010-08-12

Pemetrexed in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
32 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡